Detailed Description PHO’s laboratory performs Whole Genome Sequencing (WGS) of various organisms using Illumina NGS platforms. Preventative maintenance service is a mandatory requirement to ensure our systems are operational and meet regulatory standards.
ORDER FOR ILLUMINA NGS REAGENTS TO PERFORM DIAGNOSTIC CONFIRMATORY SEQUENCING IN SLSS Solicitation ID/Procurement Identifier: 1232SA20D0001 Ultimate Completion Date: Thu May 11 17:00:00 GMT 2023
NCO4 awarded Purchase Order 36C24423P0504 to Illumina, Inc for Delivery, Installation, Training, and Service of Illumina NG 550 DX Sequencing System for VA Pittsburgh Healthcare System for $409,923.00. Award is in accordance with FAR 13.5 Simplified Procedures for Certain Commercial Items. The statutory authority for applying the Simplified Procedures for Commercial Items of FAR 13.5 is 41 U.S.C.
FIU may terminate this Agreement immediately upon notice to Supplier for any violation of this provision.1549665950170_FIU-Standard-Terms-Conditions.pdf167.06 KB FIU-Standard-Terms-Conditions.pdf331.63 KB Illumina DNA Prep and 100M PE150 reads per sample Illumina DNA Prep and 50M PE150 reads per sample Illumina DNA Prep per sample Price includes: Quantity and quality confirmation Illumina NGS library construction from gDNA 100 Million paired-end 150
In order for DSU to continue its evaluation of NGS instruments, a maintenance contract for its existing Illumina NGS instruments is required. The contract will ensure the preventive maintenance needs, instrument failures, instrument upgrades, and other necessary items are addressed in a timely and cost-effective manner. This will in turn ensure that instrument testing can progress unhindered.
The DSU has been actively developing and optimizing workflows that require the use of Illumina NGS instruments, and three of these workflows are currently undergoing validation for use in the FBI's DNA casework. Given the near-term operational use of the Illumina NGS platform, the DSU has a need to purchase two additional MiSeq FGx instruments.
The objective of this task, NGS of sera and tissues, is to provide the FDA with a list of genes that are expressed following exposure to metal ions and particles.This collaboration between OSEL and DBCMS is supporting the development of new technologies in medical research in genetic studies.
